Research and Scholarship
Current Testing Guidelines: A Retrospective Analysis of a Community-Based Hereditary Cancer Program
Margaret Ward,(1) DNP, APRN, AGN-BC, Betty Elder,(2) PhD, RN, and Maryon Habtemariam,(2) DNP, APRN
From (1)Ascension Via Christi Hospitals, Wichita, Kansas; (2)Wichita State University, Wichita, Kansas
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Margaret Ward, DNP, APRN, AGN-BC, 817 N Emporia, Wichita, KS 67214. E-mail: email@example.com
J Adv Pract Oncol 2021;12(7):693–701 |
© 2021 Harborside™
It is estimated that 5% to 10% of all cancers are related to a hereditary cancer syndrome. However, specific cancers, such as pancreatic and ovarian cancers, are related to hereditary cancer syndromes 15% to 20% of the time. Genetic testing guidelines for hereditary cancer syndromes are frequently reviewed and updated by the National Comprehensive Cancer Network (NCCN). The purpose of this retrospective analysis is to identify carriers of pathogenic variants or hereditary cancer syndrome who do not meet NCCN criteria for testing and compare the results with previous studies. The data obtained can be used to provide recommendations to assess current guidelines for testing and evaluate the benefit of comprehensive panel testing vs. standard testing for specific hereditary cancer syndromes. This project is a retrospective review of clinical histories of patients who had multigene panel testing between September 2015 and February 2019 through a cancer outreach and risk assessment (CORA) program. Frequencies analyses were performed to analyze results. A total of 233 individuals were included in the analysis: 171 met BRCA1/2 testing criteria, 66 met Lynch syndrome criteria, and 4 met polyposis criteria. Of the individuals meeting established criteria for testing, 39 were identified with pathogenic variants. However, only 10 of these individuals were identified with a pathogenic variant associated with the criteria for which they met. Genetic testing that is limited to only those patients with genes associated with hereditary cancer syndromes may lead to exclusion of other potentially actionable genes, which may impair a patient’s ability to receive additional screening or preventative measures.
For access to the full length article, please sign in